56341-65-2

Basic information

• Product Name: Benzyl 4,6-O-Benzylidene-b-D-galactopyranoside
• Synonyms: Benzyl 4,6-O-Benzylidene-b-D-galactopyranoside;Benzyl 4,6-O-benzylidine-b-D-galactopyranoside;PhenylMethyl 4,6-O-(PhenylMethylene)-β-D-galactopyranoside
• CAS NO: 56341-65-2
• Molecular Formula: C₂₀H₂₂O₆
• Molecular Weight: 358.39
• Product Categories: Carbohydrates & Derivatives
• Mol File: 56341-65-2.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 556.97°C at 760 mmHg
• Flash Point: 290.645°C
• Appearance: /
• Density: 1.345g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.626
• Storage Temp.: Refrigerator
• Solubility: DMSO (Slightly), Methanol (Slightly)
• CAS DataBase Reference: Benzyl 4,6-O-Benzylidene-b-D-galactopyranoside(CAS DataBase Reference)
• NIST Chemistry Reference: Benzyl 4,6-O-Benzylidene-b-D-galactopyranoside(56341-65-2)
• EPA Substance Registry System: Benzyl 4,6-O-Benzylidene-b-D-galactopyranoside(56341-65-2)

Safety Data

• Hazardous Substances Data: 56341-65-2(Hazardous Substances Data)

Usage

InChI:InChI=1/C20H22O6/c21-16-17(22)20(23-11-13-7-3-1-4-8-13)25-15-12-24-19(26-18(15)16)14-9-5-2-6-10-14/h1-10,15-22H,11-12H2/t15?,16-,17?,18+,19?,20-/m1/s1

Upstream product

• 100-51-6 benzyl alcohol 
• 2280-44-6 D-Glucose 
• 1125-88-8 benzaldehyde dimethyl acetal 
• 25320-99-4 benzyl α-D-glucopyranoside 
• 10257-28-0 D-Galactose 
• 4163-60-4 β-D-galactose peracetate 
• 10343-13-2 benzyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside 
• 4304-12-5 benzyl β-D-galactopyranoside 
• 100-52-7 benzaldehyde 
• 335162-25-9 benzyl α,β-D-galactopyranoside 
• 3947-62-4 2,3,4,5-tetra-O-acetyl-D-glucopyranose 
• 604-69-3 β-D-glucose pentaacetate 
• 100-39-0 benzyl bromide 
• 83-87-4 D-glucose pentaacetate 

Downstream Products

• 67831-41-8 benzyl 2,3-di-O-benzyl-β-D-glucopyranoside 
• 83050-03-7 benzyl 4-O-benzyl-3-deoxy-2-O-methyl-β-D-ribo-hexopyranoside 
• 83050-07-1 benzyl 6-O-benzyl-3-deoxy-2-O-methyl-β-D-ribo-hexopyranoside 
• 83050-10-6 benzyl 4-O-benzyl-3-deoxy-2,6-di-O-methyl-β-D-ribo-hexopyranoside 
• 83050-14-0 benzyl 6-O-benzyl-3-deoxy-2,4-di-O-methyl-β-D-ribo-hexopyranoside 
• 83050-05-9 benzyl 6-O-benzyl-2,3-di-O-ethyl-β-D-glucopyranoside 
• 83050-02-6 benzyl 4-O-benzyl-2,3-di-O-ethyl-β-D-glucopyranoside 
• 83050-09-3 benzyl 4-O-benzyl-2,3-di-O-ethyl-6-O-methyl-β-D-glucopyranoside 
• 83050-12-8 benzyl 6-O-benzyl-2,3-di-O-ethyl-4-O-methyl-β-D-glucopyranoside 
• 82137-17-5 benzyl 4-O-benzyl-2,3-di-O-propyl-β-D-glucopyranoside 
• 83050-06-0 benzyl 6-O-benzyl-2,3-di-O-propyl-β-D-glucopyranoside 
• 83050-13-9 benzyl 6-O-benzyl-4-O-methyl-2,3-di-O-propyl-β-D-glucopyranoside 
• 82122-44-9 benzyl 4-O-benzyl-6-O-methyl-2,3-di-O-propyl-β-D-glucopyranoside 
• 154774-22-8 benzyl 4,6-O-benzylidene-2,3-O-bis(3,4,5-tris(benzyloxy)benzoyl)-β-D-glucopyranoside 

Relevant articles and documents

Exploring the Biochemical Foundations of a Successful GLUT1-Targeting Strategy to BNCT: Chemical Synthesis and in Vitro Evaluation of the Entire Positional Isomer Library of ortho-Carboranylmethyl-Bearing Glucoconjugates

Boron neutron capture therapy (BNCT) is a noninvasive binary therapeutic modality applicable to the treatment of cancers. While BNCT offers a tumor-targeting selectivity that is difficult to match by other means, the last obstacles preventing the full har

Synthesis of the trisaccharide repeating unit of capsular polysaccharide from Klebsiella pneumoniae

The incidences of primary, pyrogenic liver abscess complicated by meningitis and septic endophthalmitis caused by Klebsiella pneumoniae has increased globally. Earlier studies have shown that the capsular polysaccharide (CPS) of Klebsiella pneumoniae plays an important role in the resistance to phagocytosis and related pathogenicity. The first chemical synthesis of the trisaccharide repeating unit of this CPS has been achieved via stereoselective glycosylation with orthogonal and appropriate protecting groups. A new method for the pyruvylation of trans diol was developed.

TANNIN INHIBITORS OF HIV

The invention provides a method to prevent or treat HIV-infection with synthetic tannins, and pharmaceutical compositions comprising synthetic tannins.